

## Laxative potential of the ethanolic leaf extract of *Aloe vera* (L.) Burm. f. in Wistar rats with loperamide-induced constipation

A. O. T. Ashafa, T. O. Sunmonu<sup>1</sup>, A. A. Abass<sup>2</sup>, A. A. Ogbe<sup>2</sup>

### ABSTRACT

**Background:** Constipation is a highly prevalent and often chronic functional gastrointestinal disorder affecting humans irrespective of race and color exposing victims to colorectal cancer. The present study evaluated the efficacy of the ethanolic leaf extract of *Aloe vera* against loperamide-induced constipation in rats. **Materials and Methods:** Rats were constipation induced by the oral administration of loperamide (3 mg/kg body weight) while the control animals received normal saline. Constipated rats were treated with 50, 100, and 200 mg/kg body weight/day of the ethanolic leaf extract for 7 days during which the feeding characteristics, body weight, fecal properties, and gastrointestinal transit ratio were monitored. **Results:** Treatment of constipated rats with the extract at 50, 100, and 200 mg/kg body weight for 7 days improved intestinal motility, increased fecal volume, and normalized body weight in the constipated rats. These are indications of the laxative property of the herb with the 200 mg/kg body weight of the extract showing the best efficacy. **Conclusion:** The effect of the extract compares favorably well with Gaviscon, a standard laxative drug. These findings have therefore lent scientific support to the use of the herb as a laxative agent in Nigerian folkloric medicine.

Department of Plant Sciences,  
University of the Free  
State, Qwaqwa Campus,  
Phuthaditjhaba, South Africa,  
<sup>1</sup>Department of Biochemistry,  
University of Ilorin, Ilorin,  
<sup>2</sup>Department of Botany, Lagos  
State University, Ojo Campus,  
Lagos, Nigeria

**Key words:** *Aloe vera*, constipation, ethanolic extract, folk medicine, Gaviscon, intestinal motility

### INTRODUCTION

Constipation is a highly prevalent and often chronic functional gastrointestinal disorder affecting 3-15% of the general population.<sup>[1-4]</sup> It is a common clinical problem comprising a constellation of symptoms that include excessive straining, hard stools, feeling of incomplete evacuation, use of digital maneuvers, or infrequent defecation. A number of conditions such as metabolic problems, fiber deficiency, anorectal problems, and drugs can cause constipation. Functional constipation consists of two subtypes, namely, slow-transit constipation and dyssynergic defecation. Some patients with irritable bowel syndrome may exhibit features of both types of constipation.<sup>[5]</sup>

Laxatives are agents that add bulk to intestinal contents by retaining water within the bowel lumen by virtue of their osmotic effects, or that stimulate intestinal secretion or motility thereby increasing the frequency and ease of defecation.<sup>[6,7]</sup> The use of chemical drugs such as Senna,

Correctol, Etlax, Senokot, and Gaviscon (containing sennosides as active ingredients) for the treatment of constipation is common among affected individuals. However, the use of these orthodox drugs is limited due to their high cost, undesirable side effects (such as stomach pain and cramps), and slow activity (up to 8 h) in relieving constipation.<sup>[3,4,8]</sup> Therefore, almost half of patients with constipation are not satisfied with the efficacy of orthodox laxatives in improving quality of life.<sup>[9,10]</sup> Consequently, attention has been shifted to the use of medicinal plants for the treatment of the menace particularly in Nigeria.<sup>[11,12]</sup> There is the general belief among users that plant extracts are cheap, fast acting, and readily available coupled with the availability of several choices.<sup>[13]</sup> Therefore, the continuous search for a more natural, effective, affordable and readily available laxative of plant origin necessitated this research.

From time immemorial, aloe plants have been used medicinally for centuries for the treatment of diverse disorders and

#### Access this article online

Website: [www.jnatpharm.org](http://www.jnatpharm.org)

DOI: 10.4103/2229-5119.86268

Quick Response Code:



#### Address for correspondence:

AOT Ashafa,  
Department of Plant  
Sciences, University of  
the Free State, Qwaqwa  
Campus, Phuthaditjhaba,  
South Africa. E-mail: tom.  
ashafa@gmail.com

ailments such as diabetes and ulcer.<sup>[14]</sup> There are at least four species of the over 360 known ones that have medicinal properties – *Aloe arborescens* Miller; *Aloe perryi* Baker; *Aloe ferox* Miller, and *Aloe barbadensis* Miller, also known as *Aloe vera*.<sup>[14,15]</sup> Among them, *A. vera* is the most widely used healing plants in the history of mankind.<sup>[16]</sup> *Aloe vera* (L.) Burm. f. is perennial, succulent xerophytes which develops water storage tissues in the leaves to survive in dry areas of low or erratic rainfall. The innermost part of the leaf is a clear, soft, moist, and slippery tissue that consists of large, thin-walled parenchyma cells in which water is held in the uniform of viscous mucilage.<sup>[17,18]</sup> *A. vera* has been part of the traditional medicine practices of many regions of the world for centuries and the medicinal efficacy has been attributed to the aggregation of over 75 bioactive phytochemicals.<sup>[19]</sup> These comprise basically polysaccharides and anthraquinones which are concentrated in the inner leaf parenchymatous tissues of the plant.<sup>[20,21]</sup> The medicinal activities of the plant have been reported to be as a result of synergistic action of the compounds (such as cellulose and aloe-emodin) contained therein rather than a single chemical substance.<sup>[22]</sup> The bioefficacy reports of *A. vera* include antimicrobial,<sup>[21,23]</sup> antiviral,<sup>[24]</sup> antioxidant,<sup>[25]</sup> anti-psoriasis,<sup>[26]</sup> antidiabetic,<sup>[27-30]</sup> cardiac stimulatory,<sup>[31]</sup> antiulcer,<sup>[32]</sup> immunomodulatory,<sup>[33,34]</sup> anti-inflammatory,<sup>[35,36]</sup> anticancer,<sup>[37]</sup> and hepatoprotective properties.<sup>[38]</sup>

Although the traditional use of *A. vera* as a laxative is known but little or no scientific credence is available in the literature on the purgative potential of this plant. The present study therefore investigated the laxative/purgative activity of *A. vera* in loperamide-induced constipated experimental animals and the effect was compared with Gaviscon, a standard laxative drug. The result from this study is expected to shed more light on the minimum required dosage of the *A. vera* crude extract that will provide an effective laxative activity.

## MATERIALS AND METHODS

### Drugs and chemicals

Loperamide hydrochloride, carmine, and carboxymethylcellulose were procured from Sigma Chemical Co. (St. Louis, MO, USA) while Gaviscon was a product of Reckitt Benckiser Pharmaceutical (Pty) Ltd. (Elandsfontein, South Africa). All other chemicals and reagents used were of analytical grade.

### Plant materials

Fresh, mature leaves of *A. vera* were collected from the Ojo area of Lagos State, Nigeria, from homes where the plant is grown in pots. The plant was authenticated by Mr. OK Oluwa, a biosystemanist in the Department of Botany, Lagos State University, and a voucher specimen

(AshMed. 2010/LHB01) was prepared and deposited in the university herbarium.

### Preparation of the ethanolic extract

The leaves of *A. vera* were thoroughly washed with distilled water, cut into thin slices, and air-dried at room temperature to a constant weight. The dried leaves were grinded into a powder and 40 g of the material was extracted by shaking it for 24 h in 500 ml of ethanol. The extract obtained was filtered through Whatman no. 1 (70 mm) filter paper and concentrated on a water bath at 45°C to give a yield of 5.2 g. This was reconstituted in distilled water to give the required doses of 50, 100, and 200 mg/kg body weight for the experiment.

### Animal used

Male albino rats (*Rattus norvegicus*) of the Wistar strain with a mean weight of 150 ± 4.22 g were bred in the animal house of the Department of Biochemistry, Lagos State University. The animals were housed individually in clean metabolic cages placed in a well-ventilated house under optimum conditions (temperature 23 ± 1°C; photoperiod: 12 h natural light and 12 h dark; humidity: 45–50%). They were acclimatized for 7 days after being selected for the experiment, during which they were allowed free access to commercial pelleted rat chow (Lagos State Agro-Products, Agric Farm, Ojo, Lagos) and water *ad libitum*. The cleaning of the cages was done on a daily basis. All animal treatments were in accordance with international ethical guidelines and the National Institute of Health Guide concerning the care and use of laboratory animals. The study was carried out following the approval from the Ethical Committee of the Lagos State University on the use and care of animals.

### Induction of constipation in the rats

Constipation was induced in the animals by the oral administration of 1 ml loperamide (3 mg/kg body weight in 0.9% sodium chloride for 3 days),<sup>[39]</sup> while the control rats were administered with the normal saline only. The passage of reduced, hard, and dry fecal pellets indicated constipation in the rats.

### Experimental design

A total of 36 Wistar rats were used for the experiment and they were grouped into 6 with each group comprising 6 animals each. Those in Groups 1 (control) and 2 (constipated control) were administered with distilled water. Groups 3, 4, and 5 comprised constipated rats given 50, 100, and 200 mg/kg body weight/day of the *A. vera* ethanolic extract, respectively, while Group 6 consisted of constipated rats administered with Gaviscon. The administration was done using a metal oropharyngeal cannula. The water intake, feed intake, and body weight gain of all the rats were recorded during the experimental period and treatment lasted for 7 days.

### Total number, dry weight, and water content of the fecal pellet

The excreted fecal pellets of individual rats were collected daily at 09:00 am throughout the duration of the experiment. The total number, weight, and water content of the pellets were determined. The water content was calculated as the difference between the wet and dry weights of the pellet.

### Gastrointestinal transit ratio

The gastrointestinal (GIT) ratio was measured according to the method of Nagakura *et al.*<sup>[40]</sup> On the day 7, 1 ml of carmine (3 g suspended in 50 ml of 0.5% carboxymethylcellulose) was orally administered to the rats. One hour after the marker was administered, the animals were humanely sacrificed and the small intestines were quickly removed. The distance over which the carmine had traveled and the total length of the small intestine were measured. The GIT ratio was expressed as the percentage of the distance travelled by the carmine relative to the total length of the small intestine.

### Statistical analysis

Data were expressed as means  $\pm$  SD of six replicates and were subjected to one-way analysis of variance (ANOVA) followed by the Duncan multiple range test to determine significant differences in all the parameters. Values were considered statistically significant at  $P < 0.05$ .

## RESULTS

The administration of loperamide significantly reduced the water intake, the number, water content, and the weight of the fecal pellets [Table 1]. This indicated that constipation had been induced in the rats. However, no

significant difference was observed in the feed intake between the control and the constipated animals.

While water consumption decreased in the untreated constipated rats, the administration of the ethanolic extract of *A. vera* significantly increased the water intake in constipated rats [Table 2]. Again, there was no significant difference in the feed intake of all the animals. Similarly, the extract significantly increased the number, water content, and weight of fecal pellets in the constipated rats in a dosage-dependent manner. The body weights of the constipated animals were also normalized following the treatment with the extract.

Loperamide significantly reduced the gastrointestinal motility in the untreated constipated rats [Figure 1]. Treatment with the *A. vera* extract, however, increased the gastrointestinal movement in a dose-dependent manner which compared favorably well with Gaviscon, a standard laxative drug.


## DISCUSSION

Plants have long been a very important source of drugs against several diseases including constipation. In Nigeria, a reasonable percentage of the population depends on herbal medicines because the international commercial medicines are becoming increasingly expensive and out

**Table 1: Effect of the loperamide administration on feed intake, water intake, and fecal properties of constipated rats**

Parameters	Normal control	Constipated rats
Feed intake	16.85 $\pm$ 1.21	18.76 $\pm$ 0.98*
Water intake	20.90 $\pm$ 1.34	9.81 $\pm$ 0.85**
Number of fecal pellets	71.14 $\pm$ 3.82	26.44 $\pm$ 1.03**
Water content of fecal pellets	1.67 $\pm$ 0.18	0.63 $\pm$ 0.12**
Weight of fecal pellets	7.02 $\pm$ 0.53	3.25 $\pm$ 0.10**

Data are mean  $\pm$  SD values ( $n = 6$ ). \*Not significantly different from normal controls ( $P < 0.05$ ). \*\*Significantly different from normal controls ( $P < 0.05$ ).



**Figure 1: Effect of the ethanolic extract of *A. vera* on the GIT ratio in rats with loperamide-induced constipation**

**Table 2: Effect of the ethanolic leaf extract of *A. vera* on feed and water intake, body weight gain, and fecal properties of constipated rats**

Parameters	Constipated + <i>A. vera</i> (mg/kg body weight)					
	Normal control	Constipated control	50	100	200	Gaviscon
Feed intake	25.29 $\pm$ 1.62 <sup>a</sup>	24.66 $\pm$ 1.40 <sup>a</sup>	23.21 $\pm$ 1.19 <sup>a</sup>	22.94 $\pm$ 1.18 <sup>a</sup>	23.30 $\pm$ 1.23 <sup>a</sup>	23.12 $\pm$ 1.25 <sup>a</sup>
Water intake	53.80 $\pm$ 2.59 <sup>a</sup>	42.80 $\pm$ 2.86 <sup>b</sup>	51.00 $\pm$ 2.85 <sup>a</sup>	53.78 $\pm$ 2.82 <sup>a</sup>	54.08 $\pm$ 2.56 <sup>a</sup>	53.40 $\pm$ 2.93 <sup>a</sup>
Number of fecal pellets	77.80 $\pm$ 2.59 <sup>a</sup>	36.80 $\pm$ 4.94 <sup>b</sup>	50.40 $\pm$ 3.25 <sup>c</sup>	62.20 $\pm$ 3.68 <sup>d</sup>	74.20 $\pm$ 3.75 <sup>a</sup>	78.00 $\pm$ 3.54 <sup>a</sup>
Water content of fecal pellets (ml)	1.87 $\pm$ 0.08 <sup>a</sup>	1.33 $\pm$ 0.04 <sup>b</sup>	1.43 $\pm$ 0.07 <sup>c</sup>	1.55 $\pm$ 0.06 <sup>c</sup>	2.14 $\pm$ 0.06 <sup>d</sup>	2.08 $\pm$ 0.07 <sup>d</sup>
Weight of fecal pellets (g)	8.77 $\pm$ 0.61 <sup>a</sup>	3.93 $\pm$ 0.27 <sup>b</sup>	6.26 $\pm$ 0.26 <sup>c</sup>	8.52 $\pm$ 0.36 <sup>a</sup>	8.84 $\pm$ 0.32 <sup>a</sup>	9.01 $\pm$ 0.25 <sup>a</sup>
Body weight gain (g)	13.20 $\pm$ 0.96 <sup>a</sup>	31.78 $\pm$ 1.00 <sup>b</sup>	12.17 $\pm$ 0.91 <sup>a</sup>	11.12 $\pm$ 1.69 <sup>a</sup>	10.48 $\pm$ 1.55 <sup>a</sup>	13.22 $\pm$ 1.11 <sup>a</sup>

Data are mean  $\pm$  SD values ( $n = 6$ ). Row values with superscripts different from the control are significantly different ( $P < 0.05$ ).

of reach coupled with the undesirable side effects.<sup>[11,12]</sup> The present study has clearly demonstrated that the aqueous extract of *A. vera* has a laxative activity, which is comparable to Gaviscon.

The use of loperamide as a constipation inducer is well documented. The drug is an opioid agonist antidiarrheal that inhibits intestinal water secretion and colonic peristalsis.<sup>[41,42]</sup> This inhibition extends fecal evacuation time and delays intestinal luminal transit.<sup>[43]</sup> Loperamide-induced constipation is therefore considered to be a model of spastic constipation.<sup>[44]</sup>

The observed reduction in the number, weight, and water content of fecal pellets following the treatment with the drug indicated induction of constipation in the rats. A similar observation was reported by Shimotoyodome *et al.*<sup>[45]</sup> and Wintola *et al.*<sup>[3]</sup> The reduction in the water consumed by the constipated animals may also be due to the effect of the drug which probably accounted for the reduction in the water content of the fecal pellets. However, the drug did not prevent the animals from feeding adequately.

The administration of the ethanolic leaf extract of *A. vera* to the constipated rats was effective in influencing the increased defecation frequency, fecal volume, and motility of the colon. These are indications of the laxative property of the plant extract. This may be due to the presence of anthranoid glycosides derivatives of which aloin is the main compound.<sup>[46]</sup> According to Izzo *et al.*,<sup>[47]</sup> aloin is metabolized by the colonic flora to reactive aloe-emodin which is responsible for the purgative activity of this plant. This compound possibly exerts its action by disturbing the equilibrium between the absorption of water from the intestinal lumen via an active sodium transport<sup>[48]</sup> and the secretion of water into the lumen by a prostaglandin-dependent mechanism.<sup>[49]</sup>

Although the feed intake did not differ among the groups, the gain in body weight was higher in the untreated constipated rats compared to the extract-treated groups. This may be due to the accumulation of fecal pellets in their bodies, thus accounting for the extra weight. This clearly indicates that the plant extract increased intestinal secretion and motility in the constipated rats. A similar observation was reported by Niwa *et al.*<sup>[50]</sup> where dietary fiber was used for the treatment of morphine-induced constipation in rats. Wintola *et al.*<sup>[3]</sup> also recorded a similar observation during the treatment of constipated rats with *A. ferox*. Of particular interest is the fact that the effect of the *A. vera* extract was dose dependent in this study. The effect of the highest dosage actually compared favorably well with Gaviscon.

The transit process of the entire gastrointestinal tract reflected the overall gastrointestinal motor activity.

Measuring the colonic transit time is useful in constipation, abdominal bloating, and refractory irritable bowel syndrome.<sup>[3]</sup> It also provides quantitative information about the colonic transit, enables the identification and characterization of transit abnormalities, and allows the assessment of the severity of the problem as well as the response to therapy.<sup>[51]</sup> In this study, carmine was used as the marker to measure the colonic movement. The *A. vera* ethanolic extract increased the intestinal motility which, in turn, enhanced colonic peristalsis in the rats. The possible mechanism of the extract in this process may be enhancing the release of fluid thereby increasing intestinal secretion. The laxative effect of the extract could also be attributed to changes in the intestinal motility, which produced an increase in the intestinal transit and colonic movement.<sup>[52]</sup> Generally, the effect of the treatment with the extract compared favorably well with Gaviscon. The present study compares favorably well with that of Wintola *et al.*<sup>[3]</sup> where an *A. ferox* extract was used. This is an indication that the herb was effective in ameliorating bowel obstruction, thereby enhancing easy movement in the intestine.

## CONCLUSION

The present study revealed that oral administration of the ethanolic extract of *A. vera* exhibited a laxative activity in rats with loperamide-induced constipation rats. This suggests the beneficial effects of the herb in improving intestinal motility. Noteworthy is the fact that the extract at the highest dose of 200 mg/kg body weight showed the best laxative action, which compared favorably with Gaviscon. These findings have lent scientific support to the use of *A. vera* as a laxative agent in Nigerian folkloric medicine.

## REFERENCES

1. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. *Am J Gastroenterol* 2004;99:750-9.
2. Muller-Lissner S. The pathophysiology, diagnosis and treatment of constipation. *Dtsch Arztebl Int* 2009;106:424-32.
3. Wintola OA, Sunmonu TO, Afolayan AJ. The effect of *Aloe ferox* Mill. in the treatment of loperamide-induced constipation in Wistar rats. *BMC Gastroenterol* 2010;10:95-9.
4. Meite S, Bahi C, Yeo D, Datte JY, Djaman JA, N'guessan DJ. Laxative activities of *Mareya micrantha* (Benth.) Mull. Arg. (Euphorbiaceae) leaf aqueous extract in rats. *BMC Complement Altern Med* 2010;10:7-11.
5. Rao SS. Constipation: evaluation and treatment. *Gastroenterol Clin North Am* 2003;32:659-83.
6. Schiller LR. Review article: the therapy of constipation. *Aliment Pharmacol Ther* 2001;15:749-63.
7. Ryu SD, Park CS, Hwang SY, Park YC, Chung WG. Spasmogenic activity and acute toxicity of *Yumijangquebo*, a herbal laxative formulation. *J Ethnopharmacol* 2005;101:197-203.
8. Erasto P, Adebola PO, Grierson DS, Afolayan AJ. An ethnobotanical study of plants used for the treatment of diabetes in the Eastern Cape Province. *Afr J Biotech* 2005;4:1458-60.
9. Bengtsson M, Ohlsson B. Psychological well-being and symptoms in



- women with chronic constipation treated with sodium picosulphate. *Gastroenterol Nurs* 2005;28:3-12.
10. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. *Aliment Pharmacol Ther* 2007;25:599-608.
  11. Fasola TR, Egunyomi A. Nigerian usage of bark in phytomedicine. *Ethno Res Appli* 2005;3:73-7.
  12. Obi RK, Iroagba II, Ojiako OA. Virucidal potential of some edible Nigerian vegetables. *Afr J Biotechnol* 2006;5:1785-8.
  13. Joshi BS, Kaul PN. Alternative medicine: herbal drugs and their critical appraisal – Part I. *Prog Drug Res* 2001;56:1-76.
  14. Rodríguez Rodríguez E, Darias Martín J, Díaz Romero C. *Aloe vera* as a functional ingredient in foods. *Crit Rev Food Sci Nutr* 2010;50:305-26.
  15. Urch D. *Aloe vera*-Nature's gift. Bristol, England: Blackdown Publications; 1999. p. 7-13.
  16. Moon EJ, Lee YM, Lee OH, Lee MJ, Lee SK, Chung MH, *et al.* A novel angiogenic factor derived from *Aloe vera* gel:  $\beta$ -sitosterol, a plant sterol. *Angiogenesis* 1999;3:117-23.
  17. Newton LE. Aloes in Habitat. In: Reynolds, editor. *Aloes: The genus Aloe*. London: CRC Press; 2004. p. 3-15.
  18. Hamman JH. Composition and applications of *Aloe vera* leaf gel. *Molecules* 2008;13:1599-616.
  19. Habeeb F, Stables G, Bradbury F, Nong S, Cameron P, Plevin R, *et al.* The inner gel component of *Aloe vera* suppresses bacterial-induced pro-inflammatory cytokines from human immune cells. *Methods* 2007;42:388-93.
  20. Ni Y, Tizard IR. Analytical methodology: The gel-analysis of aloe pulp and its derivatives. In: Reynolds, editor. *Aloes: The genus Aloe*. London: CRC Press ; 2004.p.111-26.
  21. Ni Y, Turner D, Yates KM, Tizard I. Isolation and characterization of structural components of *Aloe vera* L. leaf pulp. *Int Immunopharmacol* 2004;4:1745-55.
  22. Dagne E, Bisrat D, Viljoen A, Van Wyk BE. Chemistry of *Aloe* species. *Curr Org Chem* 2000;4:1055-78.
  23. Talmadge J, Chavez J, Jacobs L, Munger C, Chinnah T, Chow JT, *et al.* Fractionation of *Aloe vera* L. inner gel, purification and molecular profiling of activity. *Int Immunopharmacol* 2004;4:1757-73.
  24. Eshun K, He Q. *Aloe vera*: A valuable ingredient for the food, pharmaceutical and cosmetic industries-A review. *Crit Rev Food Sci Nutr* 2004;44:91-6.
  25. Ikeno Y, Hubbard GB, Lee S, Yu BP, Herlihy JT. The influence of long-term *Aloe vera* ingestion on age related disease in male Fischer 344 rats. *Phytother Res* 2002;16:712-8.
  26. Syed TA, Ahmad SA, Holt AH, Ahmad SA, Ahmad SH, Afzal M. Management of psoriasis with *Aloe vera* extract in a hydrophilic cream: a placebo-controlled, double-blind study. *Trop Med Int Health* 1996;1:505-9.
  27. Ghannam N, Kingston M, Al-Meshaal IA, Tariq M, Parman NS, Woodhouse N. The antidiabetic activity of aloes: preliminary clinical and experimental observations. *Horm Res* 1986;24:288-94.
  28. Rajasekaran S, Sivagnanam K, Subramanian S. Mineral contents of *Aloe vera* leaf gel and their role on streptozotocin-induced diabetic rats. *Biol Trace Elem Res* 2005;108:185-96.
  29. Rajasekaran S, Ravi K, Sivagnanam K, Subramanian S. Beneficial effects of *Aloe vera* leaf gel extract on lipid profile status in rats with streptozotocin diabetes. *Clin Exp Pharmacol Physiol* 2006;33:232-7.
  30. Akinmoladun AC, Akinloye O. Prevention of the onset of hyperglycaemia by extracts of *Aloe barbadensis* in rabbits treated with alloxan. *Afr J Biotechnol* 2007;6:1028-30.
  31. Yagi A, Harada N, Yamada H, Iwadare S, Nishioka I. Antibradykinin active material in *Aloe saponaria*. *J Pharm Sci* 1982;71:1172-4.
  32. Yusuf S, Agunu A, Diana M. The effect of *Aloe vera* A. Berger (Liliaceae) on gastric acid secretion and acute gastric mucosal injury in rats. *J Ethnopharmacol* 2004;93:33-7.
  33. Im SA, Oh ST, Song S, Kim MR, Kim DS, Woo SS, *et al.* Identification of optimal molecular size of modified Aloe polysaccharides with maximum immunomodulatory activity. *Int J Immunopharmacol* 2005;5:271-9.
  34. Tai-Nin Chow J, Williamson DA, Yates KM, Goux WJ. Chemical characterization of the immunomodulating polysaccharide of *Aloe vera* L. *Carbohydr Res* 2005;40:1131-42.
  35. Reynolds T, Dweck AC. *Aloe vera* leaf: a review update. *J Ethnopharmacol* 1999;68:3-37.
  36. Langmead L, Makins RJ, Rampton DS. Anti-inflammatory effects of *Aloe vera* gel in human colorectal mucosa *in vitro*. *Aliment Pharmacol Ther* 2004;19:521-7.
  37. Akev N, Turkay G, Can A, Gurel A, Yildiz F, Yardibi H, *et al.* Tumor preventive effect of *Aloe vera* pulp lectin (Aloctin I) on Ehrlich ascites tumors in mice. *Phytother Res* 2007;21:1070-5.
  38. Chandan BK, Saxena AK, Shukla S, Sharma N, Gupta DK, Suri KA, *et al.* Hepatoprotective potential of *Aloe barbadensis* Mill. against carbon tetrachloride induced hepatotoxicity. *J Ethnopharmacol* 2007;111:560-6.
  39. Bustos D, Ogawa K, Pons S, Soriano E, Bandi JC, Bustos Fernández L. Effect of loperamide and bisacodyl on intestinal transit time, fecal weight and short chain fatty acid excretion in the rat. *Acta Gastroenterol Latinoam* 1991;21:3-9.
  40. Nagakura Y, Naitoh Y, Kamato T, Yamano M, Miyata K. Compounds processing 5-HT<sub>3</sub> receptor antagonistic activity inhibit intestinal propulsion in mice. *Eur J Pharmacol* 1996;311:67-72.
  41. Hughes S, Higgs NB, Turnberg LA. Loperamide has antisecretory activity in the human jejunum *in vivo*. *Gut* 1984;25:931-5.
  42. Aikawa N, Ohmori K. Effect of *Zaldaride Maleate*, and antidiarrheal compound, on fecal pellet output induced by hyperpropulsion in gastrointestinal of rats. *Jpn J Pharmacol* 2000;82:350-2.
  43. Yamada K, Onoda Y. Comparison of the effects of T-1815, yohimbine and naloxone on mouse colonic propulsion. *J Smooth Muscle Res* 1993;29:47-53.
  44. Schiller LR, Santa Ana CA, Morawski SG, Fordtran JS. Mechanism of the antidiarrheal effect of loperamide. *Gastroenterology* 1984;86:1475-80.
  45. Shimotoyodome A, Meguro S, Hase T, Tokimitsu I, Satake T. Decreased colonic mucus in rats with loperamide-induced constipation. *Comp Biochem Physiol A Mol Integr Physiol* 2000;126:203-11.
  46. Ishii Y, Tanizawa H, Takino Y. Studies of aloe. V. Mechanism of cathartic effect. (4). *Biol Pharm Bull* 1994;17:651-3.
  47. Izzo AA, Sautebin L, Borrelli F, Longo R, Capasso F. The role of nitric oxide in aloe-induced diarrhoea in rat. *Eur J Pharmacol* 1999;368:43-8.
  48. Ishii Y, Tanizawa H, Takino Y. Studies of aloe: III. Mechanism of cathartic effect. *Chem Pharm Bull (Tokyo)* 1990;38:197-200.
  49. Capasso F, Mascolo N, Autore G, Duraccio MR. Effect of indomethacin on aloin and 1, 8 dioxianthraquinone-induced production of prostaglandins in rat isolated colon. *Prostaglandins* 1983;26:557-562.
  50. Niwa T, Nakao M, Hoshi S, Yamada K, Inagaki K, Nishida M, *et al.* Effect of dietary fiber on morphine-induced constipation in rats. *Biosci Biotechnol Biochem* 2002;66:1233-40.
  51. Degan L. [Gastrointestinal motility--physiology and methods of measurement]. *Ther Umsch* 2007;64:195-9.
  52. Capasso F, Gaginella TS. *Laxatives, a Practical Guide*. Milan: Springer Italia; 1997.

**Cite this article as:** Ashafa AO, Sunmonu TO, Abass AA, Ogbe AA. Laxative potential of the ethanolic leaf extract of *Aloe vera* (L.) Burm. f. in Wistar rats with loperamide-induced constipation. *J Nat Pharm* 2011;2:158-62.

**Source of Support:** Nil. **Conflict of Interest:** None declared.